Untitled Document

Welcome to the Individualizing Therapeutic Options and
Achieving Goals in Chronic Lymphocytic Leukemia (CLL)
registration website!

A Friday Satellite Symposium Preceding the 56th ASH Annual Meeting.

Join us for this educational event and earn up to 2.0 credit hours of continuing education.

Friday, December 5, 2014
12:30 PM – 1:00 PM – Registration and Lunch
1:00 PM – 3:00 PM – Symposium
Moscone Center, South Building
Esplanade Ballroom, Salon 308 – 2nd floor
747 Howard Street
San Francisco, California

Program Overview
This accredited activity will provide attendees with critical information, expert guidelines, and recommendations concerning evolving treatment paradigms in chronic lymphocytic leukemia (CLL) as well as address current clinical controversies. The symposium will present the most up-to-date data, recommendations, and practice standards in order to help attendees gain additional knowledge and understanding required to assess all possible therapeutic strategies for patients with CLL.

Target Audience
This activity is designed for community oncologists who may provide care to patients with CLL.

Learning Objectives
After completing the Individualizing Therapeutic Options and Achieving Goals in Chronic Lymphocytic Leukemia (CLL) activity, participants should be able to:

Faculty

Jan A. Burger, MD, PhD – Chair
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jennifer R. Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Peter Hillmen, MD, FRCP, FRCPath, PhD
Professor of Experimental Haematology
Department of Haematology
Leeds Teaching Hospitals
West Yorkshire, England

Thomas J. Kipps, MD, PhD
Professor of Medicine
Deputy Director for Research
University of California Moores Cancer Center
San Diego, California

 

Agenda

12:30 pm – 1:00 pm Registration and Lunch
1:00 pm – 1:15 pm Introduction / Case Presentation
Jan A. Burger, MD, PhD
1:15 pm – 1:40 pm Prognostic and Predictive Factors in CLL
Thomas J. Kipps, MD, PhD
1:40 pm – 2:05 pm The Value of Traditional Chemotherapy
Peter Hillmen, MD, FRCP, FRCPath, PhD
2:05 pm – 2:30 pm Changing Future Treatment Paradigms: The Role of Novel Therapies
Jennifer R. Brown, MD, PhD
2:30 pm – 2:45 pm Case Presentation Revisited
Jan A. Burger, MD, PhD
2:45 pm – 2:50 pm What is the Future of Treatment – ASH Trials to Watch
Jan A. Burger, MD, PhD
2:50 pm – 3:00 pm Closing and Q&A
Jan A. Burger, MD, PhD

Accreditation/Credit Designation

MD Anderson Cancer Center CME CREDIT
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Disclosure
The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Americans with Disabilities Act/Special Needs
MediCom Worldwide, Inc. is committed to equality of educational opportunity and does not discriminate against applicants, students, or employees on the basis of race, color, religion, sex, national origin, age, disability, veterans status, or sexual orientation. If you require reasonable accommodations for a disability in order to participate fully in this continuing education activity, please call 800-408-4242 no later than 14 days prior to the activity.

Instructions for Participation and Credit
There are no fees for participating in this activity.
Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting attendance will be distributed to participants after the conference. To obtain a certificate of either type, the following requirements must be met:
      • Submission of completed evaluation       • Submission of CME Verification Form

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242, ext. 128 or email info@practicaloncologist.com

 

Provided by MediCom Worldwide, Inc. and The University of Texas MD Anderson Cancer Center

This activity has been supported by educational grants from Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and from Teva Pharmaceuticals